Managing the cost drivers of medical injectables.
In recent years, the cost increases of medical injectables--pharmaceuticals and apparatus used to treat rare and chronic diseases--have far outstripped the rises in medical costs in general. Health plans have taken notice, and many are designing and implementing new procedures for managing these treatments. The task is complex and challenging, but identifying and addressing the cost drivers and, in particular, creating specialty pharmacy networks, hold the promise of containing the spiraling cost of medical injectables.
Deloitte Consulting, Pittsburgh, USA. kjjohnson@dc.com
Kjel A
KA
Johnson
D002908:Chronic Disease / Q000188:drug therapy* / Q000191:economics; D003363:Cost Control; D019468:Disease Management; D016527:Drug Costs; D006801:Humans; D007267:Injections / Q000191:economics; D007356:Insurance, Pharmaceutical Services; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D035583:Rare Diseases / Q000188:drug therapy* / Q000191:economics; D014481:United States